{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T23:17:12Z","timestamp":1793575032785,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009663","name":"University Health Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004089","name":"Krembil Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004089","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019210","name":"University Health Network Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019210","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ero.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EULAR Rheumatology Open"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ero.2025.12.008","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T10:59:25Z","timestamp":1767092365000},"page":"58-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Understanding the transition from psoriasis to psoriatic arthritis: the role of targeted therapy"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3540-0341","authenticated-orcid":false,"given":"Fadi","family":"Kharouf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Anacleto-Dabarno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Poddubnyy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ero.2025.12.008_bib0001","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-081860","article-title":"Advances in the management of psoriatic arthritis in adults","volume":"387","author":"Kharouf","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.ero.2025.12.008_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152639","article-title":"Comparative analysis of disease outcomes: early vs. late transition from psoriasis to psoriatic arthritis","volume":"71","author":"Kharouf","year":"2025","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.ero.2025.12.008_bib0003","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","article-title":"Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition","volume":"15","author":"Scher","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.ero.2025.12.008_bib0004","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard-2023-224148","article-title":"EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis","volume":"82","author":"Zabotti","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ero.2025.12.008_bib0005","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41584-021-00578-2","article-title":"Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study","volume":"17","author":"Perez-Chada","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"10.1016\/j.ero.2025.12.008_bib0006","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/rheumatology\/kex323","article-title":"Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort","volume":"56","author":"Tillett","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ero.2025.12.008_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2021.12.013","article-title":"Time to transition from psoriasis to psoriatic arthritis: a population-based study","volume":"52","author":"Karmacharya","year":"2022","journal-title":"Semin Arthritis Rheum"},{"issue":"suppl 2","key":"10.1016\/j.ero.2025.12.008_bib0008","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.2025-0314.139","article-title":"Psoriatic arthritis before psoriasis: patient characteristics and transition rate","volume":"52","author":"Anacleto-Dabarno","year":"2025","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.ero.2025.12.008_bib0009","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1468-3083.2009.03463.x","article-title":"The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics","volume":"24","author":"Christophers","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.ero.2025.12.008_bib0010","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/art.39494","article-title":"The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study","volume":"68","author":"Eder","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.ero.2025.12.008_bib0011","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"issue":"2","key":"10.1016\/j.ero.2025.12.008_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004314","article-title":"Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage","volume":"10","author":"Zabotti","year":"2024","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ero.2025.12.008_bib0013","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/annrheumdis-2021-220865","article-title":"Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis","volume":"81","author":"Acosta Felquer","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ero.2025.12.008_bib0014","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/art.41946","article-title":"Incidence of psoriatic arthritis among patients receiving biologic treatments for psoriasis: a nested case\u2013control study","volume":"74","author":"Rosenthal","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ero.2025.12.008_bib0015","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","article-title":"Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis","volume":"81","author":"Gisondi","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ero.2025.12.008_bib0016","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/rheumatology\/keae257","article-title":"Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development","volume":"64","author":"Floris","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.ero.2025.12.008_bib0017","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s40744-024-00680-3","article-title":"From psoriasis to psoriatic arthritis: decoding the impact of treatment modalities on the prevention of psoriatic arthritis","volume":"11","author":"Watad","year":"2024","journal-title":"Rheumatol Ther"},{"issue":"4","key":"10.1016\/j.ero.2025.12.008_bib0018","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S2665-9913(23)00034-6","article-title":"Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study","volume":"5","author":"Singla","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"10.1016\/j.ero.2025.12.008_bib0019","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.jaad.2024.06.106","article-title":"Risk of developing inflammatory arthritis in patients with psoriasis initiating treatment with biologics: a population-based analysis","volume":"91","author":"Strober","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.ero.2025.12.008_bib0020","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ard.2025.01.006","article-title":"Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with different classes of biologics","volume":"84","author":"Gisondi","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ero.2025.12.008_bib0021","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40259-024-00689-8","article-title":"Effect of biological therapy for psoriasis on the development of psoriatic arthritis: a population-based cohort study","volume":"39","author":"Cho","year":"2025","journal-title":"BioDrugs"},{"issue":"6","key":"10.1016\/j.ero.2025.12.008_bib0022","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41584-022-00776-6","article-title":"Psoriatic arthritis from a mechanistic perspective","volume":"18","author":"Schett","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"suppl 1","key":"10.1016\/j.ero.2025.12.008_bib0023","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/rheumatology\/keaa039","article-title":"Enthesitis in psoriatic arthritis (part 1): pathophysiology","volume":"59","author":"Araujo","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.ero.2025.12.008_bib0024","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1172\/JCI28508","article-title":"The IL-23\/IL-17 axis in inflammation","volume":"116","author":"Iwakura","year":"2006","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.ero.2025.12.008_bib0025","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.ero.2025.12.008_bib0026","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1093\/rheumatology\/keaf364","article-title":"TNF-alpha inhibitors reduce the incidence of PsA in patients with psoriasis: a propensity score-matched cohort study","volume":"64","author":"Piaserico","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.ero.2025.12.008_bib0027","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0002-9343(80)90363-0","article-title":"The problem of \u201cprotopathic bias\u201d in case-control studies","volume":"68","author":"Horwitz","year":"1980","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.ero.2025.12.008_bib0028","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/annrheumdis-2021-220761","article-title":"Does biologic therapy impact the development of PsA among patients with psoriasis?","volume":"81","author":"Meer","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ero.2025.12.008_bib0029","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3899\/jrheum.2023-0499","article-title":"Statistical and scientific considerations concerning the interpretation, replicability, and transportability of research findings","volume":"51","author":"Cook","year":"2024","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.ero.2025.12.008_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-063650","article-title":"Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial","volume":"12","author":"Haberman","year":"2022","journal-title":"BMJ Open"}],"container-title":["EULAR Rheumatology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S305070812500134X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S305070812500134X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T03:52:40Z","timestamp":1787716360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S305070812500134X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S305070812500134X"],"URL":"https:\/\/doi.org\/10.1016\/j.ero.2025.12.008","relation":{},"ISSN":["3050-7081"],"issn-type":[{"value":"3050-7081","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding the transition from psoriasis to psoriatic arthritis: the role of targeted therapy","name":"articletitle","label":"Article Title"},{"value":"EULAR Rheumatology Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2025.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}